Brief: Galecto Q3 Operating Income USD -3.156 Million
06/11/2025 21:30
Nov 06 (Reuters) - Galecto Q3 basic EPS USD -2.36. Q3 net income USD -3.133 million Q3 operating expenses USD 3.156 million
Recent news on Damora Therapeutics
See all newsUS RESEARCH ROUNDUP-Chevron, Exxon Mobil, GoDaddy
U.S. RESEARCH ROUNDUP-Blackstone, Hartford Insurance, Zevra Therapeutics
U.S. RESEARCH ROUNDUP- Cisco, DTE Energy, Marvell Technology
Brief: Damora Therapeutics Reports First Quarter 2026 Financial Results
Brief: Damora Therapeutics: Lori Firmani To Cease Serving As CFO Effective May 1, 2026 - SEC Filing